These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 23859330)
1. [Efficacy analysis of three therapeutic modes on clinical stage Ia nonseminomatous germ cell testicular tumors]. Dong P; Liu ZW; Li XD; Wu S; Li YH; Yao K; Qin ZK; Han H; Zhou FJ Zhonghua Wai Ke Za Zhi; 2013 Mar; 51(3):256-60. PubMed ID: 23859330 [TBL] [Abstract][Full Text] [Related]
2. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia. Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765 [TBL] [Abstract][Full Text] [Related]
3. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only. Ondrus D; Ondrusova M; Hornak M; Matoska J Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374 [TBL] [Abstract][Full Text] [Related]
4. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors. Gumus M; Bilici A; Odabas H; Ustaalioglu BBO; Kandemir N; Demirci U; Cihan S; Bayoglu IV; Ozturk T; Turkmen E; Urakci Z; Seker MM; Gunaydin Y; Selcukbiricik F; Turan N; Sevinc A World J Urol; 2017 Jul; 35(7):1103-1110. PubMed ID: 27812752 [TBL] [Abstract][Full Text] [Related]
5. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival. Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619 [TBL] [Abstract][Full Text] [Related]
6. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors]. Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998 [TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients. Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130 [TBL] [Abstract][Full Text] [Related]
8. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432 [TBL] [Abstract][Full Text] [Related]
9. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified? Divrik RT; Akdoğan B; Ozen H; Zorlu F J Urol; 2006 Oct; 176(4 Pt 1):1424-29; discussion 1429-30. PubMed ID: 16952649 [TBL] [Abstract][Full Text] [Related]
10. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy. Heidenreich A; Pfister D Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450 [TBL] [Abstract][Full Text] [Related]
14. Surgical management of low-stage nonseminomatous germ cell testicular cancer. Stephenson AJ; Klein EA BJU Int; 2009 Nov; 104(9 Pt B):1362-8. PubMed ID: 19840014 [TBL] [Abstract][Full Text] [Related]
15. Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors. Dong P; Liu ZW; Li XD; Li YH; Yao K; Wu S; Qin ZK; Han H; Zhou FJ Med Oncol; 2013 Mar; 30(1):494. PubMed ID: 23400963 [TBL] [Abstract][Full Text] [Related]